Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05613010
Other study ID # IRB00321009
Secondary ID K23DK128573
Status Recruiting
Phase N/A
First received
Last updated
Start date March 19, 2024
Est. completion date June 2026

Study information

Verified date March 2024
Source Johns Hopkins University
Contact Cyd Eaton, PhD
Phone 667-306-6201
Email ceaton4@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.


Description:

Over 1/3 of adolescents and young adults who have undergone kidney or liver transplantation are nonadherent to antirejection medicines, accounting for shockingly high rates of infections, rejection, graft loss, and even death. Recently, the American Society of Transplantation highlighted real-time adherence intervention as top priorities to address antirejection medication nonadherence, but these evidence-based intervention tools do not exist. The investigators aim to answer the American Society of Transplantation's call and fill these critical gaps in nonadherence management for adolescents and young adults with kidney or liver transplant. Specifically, electronic pillboxes yield valuable real-time daily dosing data to guide interventions for adolescents and young adult kidney or liver transplant recipients, but existing interventions have not optimally leveraged these devices' capabilities. Just-in-time adaptive interventions delivered via mobile device (i.e., Smartphone or tablet) are cutting-edge approaches that fully incorporate adolescents and young adults' daily dose behavior to automatically deliver tailored intervention content exactly when adolescents and young adults need it most. The investigators piloted a promising static medication adherence support text message intervention based on the COM-B model, a well-established behavioral health intervention model, which will be modified into a just-in-time adaptive intervention for adolescents and young adult kidney or liver transplant recipients. Given that 95% of adolescents and young adults in the USA own smartphones, the investigators hypothesize that the investigators' intervention will improve on-time dosing and reduce rejection, graft loss, and death. The investigators believe that providing adherence support text messages or praise text messages will result in a higher proportion of adolescents and young adults taking the next dose and maintaining improvements in adherence post-intervention. In summary, the investigators' just-in-time adaptive intervention leverages real-time electronic pillbox-assessed dosing behavior and Smartphone text messaging capabilities to address tacrolimus or sirolimus nonadherence when nonadherence is detected.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 13 Years to 25 Years
Eligibility Inclusion Criteria: - Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment - Currently prescribed tacrolimus or sirolimus. Exclusion Criteria: - Currently receiving dialysis - Hospitalized for duration of study - Significant developmental or cognitive delay - No access to a mobile device that supports text messaging - Decline to use electronic pill box to monitor daily medication adherence - Non-English speaking - If a participant meets inclusion criteria, enrolls in the study, and experiences graft failure potentially leading to dialysis in the case of kidney transplant recipients, the participant will be given the option to continue in the study if they remain on tacrolimus or sirolimus.

Study Design


Intervention

Behavioral:
mHealth Messaging Intervention Group
Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.

Locations

Country Name City State
United States Johns Hopkins Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Electronically-measured medication adherence (dose taken or not) Participants will use an electronic pillbox to assess daily immunosuppressant adherence (tacrolimus or sirolimus), defined as a binary variable: dose taken or not. 16 months
Secondary Standard deviation of antirejection medication dose timing This metric will be calculated as each participants' standard deviation (SD) in tacrolimus or sirolimus daily dose timing during the study based on how many minutes early/late tacrolimus or sirolimus was timestamped as taken (administered) from when it is prescribed (e.g., how many minutes before/after AYA's expected dose time) using time stamp data from the electronic pill boxes. 16 months
See also
  Status Clinical Trial Phase
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Recruiting NCT04316715 - Life-Steps Counseling to Enhance Adherence and Engagement in PrEP Care N/A
Active, not recruiting NCT04602468 - Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Phase 4
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Enrolling by invitation NCT04676204 - Relationship Between Oral DMT Burden and Adherence in MS
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Completed NCT05168449 - The Impact of Pharmacist-led Mobile Application on Adherence in Chronic Kidney Disease Patients N/A
Active, not recruiting NCT04612088 - Intervention for Multivitamin Adherence on Bariatric Patients N/A
Completed NCT03958331 - Behavioral Economics and Adherence in Teens (BEAT!) N/A
Completed NCT05233644 - Medication Adherence in Heart Failure After Hospitalisation
Completed NCT03837496 - Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors N/A
Recruiting NCT03683966 - MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
Withdrawn NCT04754867 - Pre-Test of For the Future Self and Smoking Cessation N/A
Recruiting NCT05996094 - Antiretroviral Adherence and Drug-level Monitoring
Not yet recruiting NCT06056037 - Making ART Work Among Brazilian Youth N/A
Completed NCT03651596 - Leveraging mHealth Messaging to Promote Adherence in Teens With CKD N/A
Completed NCT03842436 - Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use Phase 4
Completed NCT03658252 - Efficacy of Targeted Intervention for Topical Steroid Phobia. N/A
Completed NCT03081559 - Improving Engagement in HIV Care for High-risk Women N/A
Recruiting NCT05515497 - BMT4me: Post-HSCT Medication Adherence mHealth App N/A